Skip to main content

Table 2 Association between metformin, dipeptidyl peptidase-4 inhibitors, insulin, and metformin plus dipeptidyl peptidase-4 inhibitors and study outcomes after propensity score matching

From: Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Outcomes

Treatment groups

Conditional logit logistic regression

Mixed effect logistic regression

OR (95% CI)

p value

OR (95% CI)

p value

 

Metformin (n = 249)

Other GLD (n = 249)

p value

 

In-hospital deaths

79 (31.7%)

79 (31.7%)

1.000

1.15 (0.78–1.71)

0.482

1.16 (0.78–1.72)

0.482

ICU admission, mechanical ventilation, or in-hospital death

91 (36.5%)

88 (35.4%)

0.852

1.05 (0.73–1.51)

0.780

1.05 (0.73–1.52)

0.779

In-hospital complications

146 (58.6%)

139 (55.8%)

0.587

1.18 (0.81–1.72)

0.392

1.17 (0.81–1.70)

0.398

Long-time hospital stay

59 (23.7%)

45 (18.1%)

0.152

1.49 (0.95–2.31)

0.079

1.49 (0.96–2.33)

0.075

 

DPP-4i (n = 105)

Other GLD (n = 105)

p value

 

In-hospital deaths

41 (39.0%)

44 (41.9%)

0.779

1.05 (0.66–2.13)

0.521

1.05 (0.67–2.11)

0.562

ICU admission, mechanical ventilation, or in-hospital death

45 (42.9%)

42 (40.0%)

0.780

1.12 (0.65–1.92)

0.680

1.12 (0.65–1.95)

0.675

In-hospital complications

66 (62.9%)

70 (66.7%)

0.665

0.94 (0.67–2.12)

0.480

0.94 (0.67–2.13)

0.481

Long-time hospital stay

23 (21.9%)

24 (22.9%)

1.000

0.83 (0.38–1.46)

0.400

0.84 (0.39–1.46)

0.406

 

Insulin (n = 129)

Other GLD (n = 129)

p value

 

In-hospital deaths

51 (39.5%)

46 (35.7%)

0.607

1.15 (0.65–1.97)

0.590

1.15 (0.65–1.97)

0.598

ICU admission, mechanical ventilation, or in-hospital death

57 (44.2%)

54 (41.9%)

0.802

1.10 (0.67–1.80)

0.710

1.10 (0.67–1.81)

0.706

In-hospital complications

49 (38.9%)

46 (35.7%)

0.796

1.00 (0.58–1.67)

0.930

1.00 (0.57–1.67)

0.912

Long-time hospital stay

22 (17.1%)

34 (26.4%)

0.097

0.63 (0.37–1.20)

0.158

0.63 (0.37–1.21)

0.159

 

Metformin + DPP-4i (n = 127)

Other GLD (n = 127)

p value

 

In-hospital deaths

29 (22.8%)

37 (29.1%)

0.317

0.73 (0.40–1.28)

0.270

0.72 (0.39–1.27)

0.251

ICU admission, mechanical ventilation, or in-hospital death

40 (31.5%)

45 (35.4%)

0.592

0.84 (0.50–1.41)

0.510

0.84 (0.49–1.41)

0.503

In-hospital complications

67 (52.8%)

70 (55.1%)

0.801

0.87 (0.51–1.46)

0.596

0.86 (0.50–1.47)

0.592

Long-time hospital stay

29 (22.8%)

26 (20.5%)

0.761

1.17 (0.62–2.23)

0.627

1.17 (0.62–2.19)

0.632

  1. Data are shown as absolute values and percentages. A significant imbalance in the group was considered if a standardized mean difference between baseline variables of greater than 10% was found. Values were considered to be statistically significant when p < 0.05
  2. DPP-4i dipeptidyl peptidase-4 inhibitors, GLD glucose-lowering drugs, ICU intensive care unit, OR odds ratio, 95% CI 95% confidence interval